- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01829204
Prospective Data Bank Creation to Study Vaginal Conditions (CRIPB-13-002)
A Prospective Longitudinal Data Bank Creation to Study Vaginal Conditions With a Novel Diagnostic Approach
Study Overview
Status
Conditions
Detailed Description
Our approach specifically targets the evaluation of the proteins and cytokines present and the bacteriological analysis of the microflora in the vaginal milieu.
Conjectures:
- An initial insult in the vagina (possibly involving a bacterial, viral or fungal organism or their products) causes modifications in the vaginal milieu
- The vaginal milieu responds to the insult by developing an inflammatory reaction characterized by cytokine and protein production
- Long lasting or repetitive insults maintain biochemical changes in the vaginal milieu producing a reaction, chemical irritation or micro flora alteration by changes in proteins and/or abnormal protein production
- Those changes eventually result in hypersensitivity, irritation, burning, and pain manifested in patients with vulvodynia. And those changes may also result in the recurrence of fungal or bacterial infections
- Those changes may also contribute to initiate the cascade of premature events conducting to cervical effacement and dilation observed in preterm labor
The conjectures will be investigated by using a multidisciplinary approach including: microbiology, proteomics and cytokines evaluation of the vaginal milieu. Specifically we will be comparing an asymptomatic female population to serve as a baseline to patients affected by vulvodynia, recurrent fungal or bacterial vaginosis and/or pregnancy.
This is a prospective, descriptive study of about 550 women age 12 to 75 years. There will be four groups: 1) Asymptomatic healthy women, 2) Women being seen for any gynecological vulvovaginal condition, and 3) Pregnant women who are asymptomatic and healthy, and 4) Pregnant women have any gynecological vulvovaginal condition.
We will evaluate the following:
- Types of cytokines normally present in women and in patients with vulvodynia, recurrent fungal and bacterial vaginosis and preterm labor
- Normal microbiology flora in women and variations present in the vaginal milieu in these patients
- The presence of normal and atypical proteins in the vaginal milieu of healthy women and patients with vulvodynia, recurrent fungal and bacterial vaginosis and preterm labor
- Informed consent will be obtained and documented for participation in the study
- Comprehensive history assessment of environmental factors, topical vulvovaginal issues and co morbid conditions as defined in the exclusion criteria.
- Pelvic examination to obtain two samples via cotton swabs for proteomics, cytokines, vaginal lactobacillus from vaginal secretions.
A. Swab procedure:
The cotton swabs (2) will be introduced only in the middle vagina, one at the time, no other areas will be sampled.
B. Swab processing One swab will be placed in a special room temperature solution. This de-identified swab will be mailed for Lactobacillus.
The second de-identified swab is to be place in 2 separated micro-containers in Liquid Nitrogen Containers (one for cytokines and one for Proteomics). When 50 samples are completed they will be processed at TTUHSC Permian Basin campus, with the Proteomics testing being done in Lubbock.
Therefore, there are 3 samples, each processed differently. Data will be recorded in a confidential manner with no personal identifiers, only an assigned study subject number. As such, the de-identified data may serve as a database for additional studies. The computer used will belong to TTUHSC and be password protected, access limited to only authorized personnel. Consent forms will be stored separately from the study data in the research office.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Texas
-
Midland, Texas, United States, 79701
- Recruiting
- TTUHSC Permian Basin
-
Contact:
- Ailena R Mulkey, RN
- Phone Number: 432-703-5388
- Email: ailena.mulkey@ttuhsc.edu
-
Principal Investigator:
- Gary Ventolini, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
All patients willing to participate, and give informed consent, and Asymptomatic, non-pregnant, healthy women ages 21 to 75 years with no previous history of any chronic or recurrent vulvovaginal condition who attend our clinical offices for their annual well-woman physical examination.
2-Non-pregnant women ages 21 to 75 years being evaluated for any gynecological vulvovaginal condition.
Pregnant women ages 21 to 75 years who are both asymptomatic and healthy Pregnant women ages 21 to 75 who have any gynecological vulvovaginal condition
Description
Inclusion Criteria:
- All patients willing to participate, and give informed consent, and
- Asymptomatic, non-pregnant, healthy women ages 21 to 75 years with no previous history of any chronic or recurrent vulvovaginal condition who attend our clinical offices for their annual well-woman physical examination.
- Non-pregnant women ages 21 to 75 years being evaluated for any gynecological vulvovaginal condition.
- Pregnant women ages 21 to 75 years who are both asymptomatic and healthy
- Pregnant women ages 21 to 75 who have any gynecological vulvovaginal condition
Exclusion Criteria:
- Asymptomatic patients ages < 21 or > 75, or symptomatic patients ages < 21 or > 75 years.
- Patients diagnosed with cancer or having any medical condition that is not under control including: diabetes mellitus, hypertension, collagen disease, hemoglobinopathy, renal insufficiency, depression, anxiety, psychosis and panic attacks
- Patients unable to follow the protocol or unwilling to participate
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Non pregnant asymptomatic
Asymptomatic, non-pregnant, healthy women ages 21 to 75 years with no previous history of any chronic or recurrent vulvovaginal condition who attend our clinical offices for their annual well-woman physical examination
|
Non pregnant symptomatic
Non-pregnant women ages 12 to 75 years being evaluated for any gynecological vulvovaginal condition.
|
Pregnant asymptomatic
Pregnant women ages 12 to 75 years who are both asymptomatic and healthy
|
Pregnant symptomatic
Pregnant women ages 12 to 75 who have any gynecological vulvovaginal condition
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cytokines Determination
Time Frame: one time for all except pregnant patients 4 times 12 months
|
To determine types of cytokines normally present in women's vagina and in patients with vulvodynia, recurrent fungal and bacterial vaginosis and preterm labor
|
one time for all except pregnant patients 4 times 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proteins Determination
Time Frame: one time for all except pregnant patients 4 times 12 months
|
The vaginal milieu will respond to the insult by developing an inflammatory reaction characterized by protein production (in terms of increased protein concentration according to the Bradford protein assay).
|
one time for all except pregnant patients 4 times 12 months
|
Lactobacillus determination
Time Frame: one time for all except pregnant patients 4 times 12 months
|
Long lasting or repetitive insults maintain biochemical changes in the vaginal milieu producing lactobacillus microflora alteration.
|
one time for all except pregnant patients 4 times 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Michael L Galloway, DO, TTUHSC PB
Publications and helpful links
General Publications
- Verstraelen H, Verhelst R, Claeys G, De Backer E, Temmerman M, Vaneechoutte M. Longitudinal analysis of the vaginal microflora in pregnancy suggests that L. crispatus promotes the stability of the normal vaginal microflora and that L. gasseri and/or L. iners are more conducive to the occurrence of abnormal vaginal microflora. BMC Microbiol. 2009 Jun 2;9:116. doi: 10.1186/1471-2180-9-116.
- Ventolini G, Barhan SM. Vulvodynia. Dermatol Online J. 2008 Jan 15;14(1):2.
- Ventolini G, Barhan S, Duke J. Vulvodynia, a step-wise therapeutic prospective cohort study. J Obstet Gynaecol. 2009 Oct;29(7):648-50. doi: 10.1080/01443610903095882.
- Ventolini G. Measuring treatment outcomes in women with vulvodynia. J Clin Med Res. 2011 Apr 4;3(2):59-64. doi: 10.4021/jocmr526w.
- Ventolini G. Vulvar pain: Anatomic and recent pathophysiologic considerations. Clin Anat. 2013 Jan;26(1):130-3. doi: 10.1002/ca.22160. Epub 2012 Sep 5.
- Omoigui S. The biochemical origin of pain: the origin of all pain is inflammation and the inflammatory response. Part 2 of 3 - inflammatory profile of pain syndromes. Med Hypotheses. 2007;69(6):1169-78. doi: 10.1016/j.mehy.2007.06.033. Epub 2007 Aug 28.
- Traisnel G, Lablanche JM, Fourrier JL, Marquand A, Bertrand ME. [Reproducibility of the exercise test and coronary vasomotor tonus]. Arch Mal Coeur Vaiss. 1988 Jun;81(6):765-72. French.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Pregnancy Complications
- Obstetric Labor Complications
- Vaginal Diseases
- Vulvar Diseases
- Vaginitis
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Mycoses
- Vaginosis, Bacterial
- Obstetric Labor, Premature
- Vulvodynia
Other Study ID Numbers
- L13-054
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mycoses
-
Steven B. KleiboekerNational Institute of Allergy and Infectious Diseases (NIAID)WithdrawnAdenovirus | Other MycosesUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
Fungal Infection Study ForumMerck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Xiamen Amoytop Biotech Co., Ltd.Shanghai Jiao Tong University Affiliated First People's HospitalCompleted
-
Institut National de la Santé Et de la Recherche...UnknownCandidiasisBelgium, France, Italy, Netherlands, Spain
-
PfizerVicuron PharmaceuticalsCompleted
-
Daniel BenjaminEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedFluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams BirthweightCandidiasisUnited States
-
Merck Sharp & Dohme LLCCompleted